A one-two punch of changing gene expression, then deploying immune checkpoint inhibitors, shows promise in battling one of the most treatment-resistant types of cancer in preclinical models, according to a new publication including authors from the Hackensack Meridian Center for Discovery and Innovation (CDI).
Hackensack Meridian CDI Scientists Find One-Two Punch Working against Stubborn Pancreatic Cancer in Preclinical Models
